- GSK Pharma India’s net income for Q1 is 1.82 billion rupees, which is a 38% increase year-over-year.
- The net income exceeded the estimated 1.71 billion rupees.
- The company’s revenue is 8.1 billion rupees, representing a 6.3% increase year-over-year but falling short of the 8.25 billion rupees estimate.
- Total costs for the quarter are 6 billion rupees, a decrease of 5.4% year-over-year.
- Other income stands at 356.4 million rupees, a decline of 2.2% year-over-year.
- Shares of GSK Pharma India rose by 3.2% to 2,847 rupees with 253,598 shares traded.
- Analyst ratings for the stock: 2 buys, 2 holds, and 0 sells.
A look at GlaxoSmithKline PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
GlaxoSmithKline PLC, a research-based pharmaceutical company, is positioned with mixed scores according to Smartkarma Smart Scores. While the company scores high in Dividend and Growth, indicating a strong payout to shareholders and potential for expansion, it falls short in Value and Resilience. The moderate score in Momentum suggests a steady performance in the market. Overall, GlaxoSmithKline remains a stable player in the pharmaceutical industry, offering a range of products for various health conditions.
Considering the Smartkarma Smart Scores for GlaxoSmithKline PLC, investors may find the company appealing for its solid dividend payouts and growth potential. However, the lower scores in Value and Resilience indicate some challenges that the company may need to address for long-term sustainability. With its diverse portfolio of vaccines, prescription drugs, and consumer health products, GlaxoSmithKline is positioned to navigate the competitive pharmaceutical landscape while aiming for growth and shareholder returns.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
